283 related articles for article (PubMed ID: 8869093)
1. Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer.
Sagaster P; Flamm J; Flamm M; Mayer A; Donner G; Oberleitner S; Havelec L; Lepsinger L; Ludwig H
Eur J Cancer; 1996 Jul; 32A(8):1320-4. PubMed ID: 8869093
[TBL] [Abstract][Full Text] [Related]
2. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
[TBL] [Abstract][Full Text] [Related]
3. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
5. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
[TBL] [Abstract][Full Text] [Related]
6. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF
Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of neoadjuvant chemotherapy in invasive bladder cancer.
Cam K; Yildirim A; Ozveri H; Turkeri L; Akdas A
Int Urol Nephrol; 2002; 33(1):49-52. PubMed ID: 12090338
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant CMV chemotherapy plus radical cystectomy in locally advanced bladder cancer: the impact of pathologic response on long-term results.
Scattoni V; Bolognesi A; Cozzarini C; Francesca F; Grasso M; Galli L; Torelli T; Campo B; Villa E; Rigatti P
Tumori; 1996; 82(5):463-9. PubMed ID: 9063525
[TBL] [Abstract][Full Text] [Related]
10. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
13. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
15. Conservative management of advanced bladder cancer.
Lekili M; Ayder AR; Minareci S; Nergis S; Durgun MN
Int Urol Nephrol; 1995; 27(6):747-52. PubMed ID: 8725041
[TBL] [Abstract][Full Text] [Related]
16. [Neoadjuvant chemotherapy (M-VAC) in invasive cancer of the bladder. Our experience].
González Enguita C; Caro Cebrián C; Roncalés Badal A; Gil Sanz MJ; Martínez Bengoechea J; Rioja Sanz LA
Arch Esp Urol; 1990; 43 Suppl 2():197-204. PubMed ID: 2096779
[TBL] [Abstract][Full Text] [Related]
17. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
Plimack ER; Hoffman-Censits JH; Viterbo R; Trabulsi EJ; Ross EA; Greenberg RE; Chen DY; Lallas CD; Wong YN; Lin J; Kutikov A; Dotan E; Brennan TA; Palma N; Dulaimi E; Mehrazin R; Boorjian SA; Kelly WK; Uzzo RG; Hudes GR
J Clin Oncol; 2014 Jun; 32(18):1895-901. PubMed ID: 24821881
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
[TBL] [Abstract][Full Text] [Related]
19. [Conservative treatment of locally advanced bladder carcinoma: neoadjuvant chemotherapy, TUR and radiotherapy. Results in 40 patients].
Serretta V; Vasile P; Falletta V; Piazza F; Pavone C; Pavone-Macaluso M
Arch Ital Urol Androl; 1998 Jun; 70(3 Suppl):37-40. PubMed ID: 9707769
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
Choueiri TK; Jacobus S; Bellmunt J; Qu A; Appleman LJ; Tretter C; Bubley GJ; Stack EC; Signoretti S; Walsh M; Steele G; Hirsch M; Sweeney CJ; Taplin ME; Kibel AS; Krajewski KM; Kantoff PW; Ross RW; Rosenberg JE
J Clin Oncol; 2014 Jun; 32(18):1889-94. PubMed ID: 24821883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
